3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Tumor-Agnostic
1
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
lutetium Lu 177 dotatate
6
Everolimus
6
lanreotide
5
anlotinib
5
Temozolomide
5
Injections
4
Dexmedetomidine
4
Cisplatin
4
surufatinib
3
Thyrotropin Alfa
3
Sodium Chloride
3
Saline Solution
3
Fluorodeoxyglucose F18
3
Blood Specimen Collection
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
(177)Lu-DOTA-EB-TATE
3
sintilimab
2
penpulimab
2
cabozantinib
2
Surgical Procedures, Operative
2
Sorafenib
2
Rosiglitazone
2
Radiotherapy
2
Radiofrequency Ablation
2
Positron Emission Tomography Computed Tomography
2
Paclitaxel
2
Nivolumab
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Metformin
2
Magnetic Resonance Spectroscopy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Clinical Trials, Phase II as Topic
×
Endocrine
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled